Accelrys Buys Chemsw In Deal Worth Up To $17.3M

NewsGuard 100/100 Score

Accelrys said it acquired ChemSW, a provider of environmental health & safety (EH&S) compliance software solutions for managing chemical sources, use, and disposal, in a deal that could cost the acquiring company up to $17.3 million.

By acquiring ChemSW, Accelrys said, it can offers customers an automated inventory system that monitors and tracks location and quantity specifics, monitors usage, generates reports, and assesses hazard information during emergencies. The system is available both on premises and via cloud computing.

Accelrys also said its customers can use ChemSW's EH&S software to help support their sustainability efforts by addressing three key areas: improving operational efficiency, delivering innovation, and meeting compliance requirements.

Accelrys agreed to acquire all ChemSW shares for $15.3 million, then pay out up to $2 million to unspecified ChemSW executives tied to undisclosed operating milestones during the first two years following the date of the closing. Accelrys said it will retain the entire ChemSW management team and employees as part of the deal, disclosed yesterday.

"The ChemSW team looks forward to joining Accelrys and working together to deliver new value to the scientific ecosystem," Brian Stafford, ChemSW's president and CEO, said in a statement.


Genetic Engineering & Biotechnology News (GEN) Genetic Engineering & Biotechnology News (GEN)This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring how intense ultrasound can release biological indicators of disease